ELIXIR PHARMACEUTICALS ACQUIRES LATE-STAGE PRODUCT FOR THE TREATMENT OF TYPE II DIABETES

Elixir Licenses Exclusive U.S., Canadian and Latin American Rights from Kissei Pharmaceutical for Glufast; Product Will Enter Growing $6 Billion Diabetes Prescription Pharmaceutical Market Elixir Pharmaceuticals, Inc. announced today that the Company has signed a definitive agreement with Kissei Pharmaceutical for the exclusive right to develop and commercialize Glufast (mitiglinide calcium hydrate) in the United States, Canada, and Latin America.
Genetic Engineering News